​

Exact Sciences (EXAS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EXAS Stock Forecast

Exact Sciences stock forecast is as follows: an average price target of $77.43 (represents a 30.35% upside from EXAS’s last price of $59.40) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

EXAS Price Target

The average price target for Exact Sciences (EXAS) is $77.43 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $95.00 to $65.00. This represents a potential 30.35% upside from EXAS's last price of $59.40.

EXAS Analyst Ratings

Buy

According to 17 Wall Street analysts, Exact Sciences's rating consensus is 'Buy'. The analyst rating breakdown for EXAS stock is 1 'Strong Buy' (5.88%), 15 'Buy' (88.24%), 1 'Hold' (5.88%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Exact Sciences Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Catherine SchulteRobert W. Baird$67.00$72.42-7.48%12.79%
Nov 06, 2024Mark MassaroBTIG$65.00$72.42-10.25%9.43%
Oct 29, 2024Kyle MiksonCanaccord Genuity$95.00$69.3536.99%59.93%
Oct 01, 2024Vijay KumarEvercore ISI$80.00$68.1217.44%34.68%
Sep 16, 2024Mark MassaroBTIG$82.00$69.4818.02%38.05%
Sep 16, 2024Patrick DonnellyCitigroup$80.00$67.9017.82%34.68%
Sep 13, 2024Kyle MiksonCanaccord Genuity$75.00$67.3911.29%26.26%
Sep 12, 2024David WestenbergPiper Sandler$85.00$66.9327.00%43.10%
Jul 19, 2024David WestenbergPiper Sandler$80.00$46.8170.90%34.68%
Jun 26, 2024Sung Ji NamScotiabank$70.00$44.1658.51%17.85%
Jun 26, 2024Mark MassaroBTIG$70.00$41.3769.20%17.85%
Jun 03, 2024Tycho PetersonJefferies$75.00$45.4565.02%26.26%
May 09, 2024Kyle MiksonCanaccord Genuity$85.00$59.4842.91%43.10%
Jun 22, 2023Patrick DonnellyCitigroup$130.00$94.5837.45%118.86%
Dec 16, 2022Matthew SykesGoldman Sachs$65.00$55.2017.76%9.43%
Aug 17, 2022David WestenbergPiper Sandler$40.00$39.561.11%-32.66%
Aug 15, 2022Catherine SchulteRobert W. Baird$75.00$43.6171.98%26.26%
Aug 03, 2022Craig-Hallum$60.00$46.9527.81%1.01%
Aug 03, 2022BTIG$70.00$46.2051.52%17.85%
Apr 29, 2022Andrew CooperRaymond James$80.00$55.6743.70%34.68%
Apr 27, 2022Leerink Partners$95.00$58.6362.03%59.93%
Apr 19, 2022Goldman Sachs$85.00$68.9823.22%43.10%
Jan 19, 2022Brandon CouillardJefferies$140.00$76.1383.90%135.69%
Nov 03, 2021Daniel AriasStifel Nicolaus$125.00$94.3232.53%110.44%
Oct 14, 2021Daniel BrennanCowen & Co.$135.00$97.7538.11%127.27%
Sep 15, 2021Kyle Mikson CFACanaccord Genuity$160.00$104.6552.89%169.36%
Aug 03, 2021Vijay KumarEvercore ISI$145.00$104.2139.14%144.11%
Jun 03, 2021Matthew SykesGoldman Sachs$160.00$107.9148.27%169.36%
May 12, 2021Sandy DraperGuggenheim$168.00$96.1174.80%182.83%

The latest Exact Sciences stock forecast, released on Nov 06, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $67.00, which represents a -7.48% decrease from the stock price at the time of the forecast ($72.42), and a 12.79% increase from EXAS last price ($59.40).

Exact Sciences Price Target by Period

1M3M12M
# Anlaysts-413
Avg Price Target-$76.75$77.62
Last Closing Price$59.40$59.40$59.40
Upside/Downside-100.00%29.21%30.67%

In the current month, the average price target of Exact Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exact Sciences's last price of $59.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2024Wells FargoBuyBuyHold
Oct 29, 2024Piper SandlerUnderperformUnderperformHold
Oct 29, 2024Canaccord GenuityBuyBuyHold
Oct 04, 2024Leerink PartnersOutperformOutperformHold
Oct 01, 2024Wells FargoBuyBuyHold
Oct 01, 2024Piper SandlerUnderperformUnderperformHold
Sep 16, 2024BTIGBuyBuyHold
Sep 16, 2024CitigroupBuyBuyHold
Sep 13, 2024Canaccord GenuityBuyBuyHold
Sep 12, 2024Piper SandlerOverweightOverweightHold
Sep 12, 2024Evercore ISIOutperformOutperformHold
Aug 27, 2024Wells FargoEqual-WeightOverweightInitialise
Aug 01, 2024BenchmarkBuyBuyHold
Jul 19, 2024Piper SandlerOverweightOverweightHold
Jun 26, 2024ScotiabankOutperformSector OutperformInitialise
Jun 26, 2024ScotiabankOutperformInitialise
Jun 26, 2024BTIGBuyBuyHold
Jun 24, 2024Cowen & Co.BuyBuyHold
May 24, 2024Cowen & Co.BuyBuyHold
May 09, 2024Canaccord GenuityBuyBuyHold
Apr 15, 2024William BlairOutperformOutperformHold
Apr 03, 2024CitigroupBuyBuyHold
Oct 10, 2023WedbushOutperformInitialise
Oct 10, 2023Exane BNP ParibasNeutralInitialise
Jun 23, 2023Canaccord GenuityBuyBuyHold
Jun 22, 2023BenchmarkBuyBuyHold
Jun 22, 2023CitigroupBuyBuyHold
Jun 12, 2023JefferiesBuyBuyHold
May 10, 2023William BlairOutperformOutperformHold
Mar 15, 2023BenchmarkBuyBuyHold
Feb 22, 2023Canaccord GenuityBuyBuyHold
Dec 16, 2022Goldman SachsBuyBuyHold
Nov 07, 2022CFRAStrong BuyUpgrade
Aug 17, 2022Piper SandlerOverweightOverweightHold
Aug 03, 2022Craig-HallumBuyBuyHold
Aug 03, 2022BTIGBuyBuyHold
Apr 27, 2022Raymond JamesOutperformOutperformHold
Apr 27, 2022SVB LeerinkOutperformOutperformHold
Feb 23, 2022Wells FargoEqual-WeightEqual-WeightHold
Feb 23, 2022CitigroupNeutralNeutralHold
Feb 23, 2022Raymond JamesOutperformOutperformHold
Feb 23, 2022SVB LeerinkOutperformOutperformHold

Exact Sciences's last stock rating was published by Wells Fargo on Oct 29, 2024. The company gave EXAS a "Buy" rating, the same as its previous rate.

Exact Sciences Financial Forecast

Exact Sciences Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$628.34M$622.09M$602.45M$553.00M$523.07M$521.64M$486.57M$473.81M$456.38M$434.82M$402.08M$466.34M$408.36M$268.87M$347.82M$295.57M$218.81M
Avg Forecast$893.94M$874.64M$856.43M$788.91M$802.26M$789.09M$762.28M$698.34M$694.92M$716.80M$690.02M$627.35M$638.83M$616.79M$601.14M$543.45M$527.21M$501.70M$498.99M$463.11M$449.11M$430.03M$420.98M$388.57M$443.96M$337.43M$228.42M$349.13M$297.43M$216.12M
High Forecast$907.74M$888.14M$869.65M$801.09M$814.64M$801.27M$774.05M$705.81M$698.20M$717.02M$690.02M$627.35M$654.37M$624.98M$610.42M$551.84M$535.35M$501.70M$498.99M$463.11M$449.11M$430.03M$420.98M$388.57M$443.96M$337.43M$228.42M$349.13M$297.43M$216.12M
Low Forecast$879.85M$860.86M$842.93M$776.47M$789.61M$776.65M$750.26M$685.40M$691.38M$716.59M$690.02M$627.35M$631.20M$609.68M$591.66M$534.89M$518.90M$501.70M$498.99M$463.11M$449.11M$430.03M$420.98M$388.57M$443.96M$337.43M$228.42M$349.13M$297.43M$216.12M
# Analysts10755854111493471788771271489151077986
Surprise %-------------1.02%1.03%1.11%1.05%1.04%1.05%1.05%1.05%1.06%1.03%1.03%1.05%1.21%1.18%1.00%0.99%1.01%

Exact Sciences's average Quarter revenue forecast for Dec 23 based on 7 analysts is $638.83M, with a low forecast of $631.20M, and a high forecast of $654.37M. EXAS's average Quarter revenue forecast represents a 1.67% increase compared to the company's last Quarter revenue of $628.34M (Sep 23).

Exact Sciences EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111493471788771271489151077986
EBITDA-------------$72.03M$-76.93M$-54.52M$-92.54M$-84.99M$-102.56M$-130.75M$-176.51M$-121.36M$-124.34M$-225.66M$-375.24M$-158.79M$-24.18M$-51.71M$-66.92M$-17.41M
Avg Forecast$-212.97M$-208.38M$-204.04M$-187.95M$-191.13M$-187.99M$-181.61M$-166.37M$-165.56M$-170.77M$-164.39M$-164.50M$-152.20M$-146.94M$-143.21M$-149.54M$-149.36M$-121.90M$-121.24M$-135.95M$-109.12M$-104.49M$-102.29M$-370.69M$-107.87M$-81.99M$-55.50M$-41.19M$-72.27M$-52.51M
High Forecast$-209.61M$-205.09M$-200.82M$-184.99M$-188.12M$-185.03M$-178.74M$-163.29M$-164.72M$-170.72M$-164.39M$-131.60M$-150.38M$-145.25M$-140.96M$-119.63M$-119.49M$-121.90M$-121.24M$-108.76M$-109.12M$-104.49M$-102.29M$-296.55M$-107.87M$-81.99M$-55.50M$-32.95M$-72.27M$-52.51M
Low Forecast$-216.26M$-211.59M$-207.18M$-190.85M$-194.08M$-190.90M$-184.41M$-168.15M$-166.34M$-170.82M$-164.39M$-197.39M$-155.90M$-148.89M$-145.43M$-179.45M$-179.23M$-121.90M$-121.24M$-163.14M$-109.12M$-104.49M$-102.29M$-444.83M$-107.87M$-81.99M$-55.50M$-49.43M$-72.27M$-52.51M
Surprise %--------------0.49%0.54%0.36%0.62%0.70%0.85%0.96%1.62%1.16%1.22%0.61%3.48%1.94%0.44%1.26%0.93%0.33%

7 analysts predict EXAS's average Quarter EBITDA for Dec 23 to be $-152.20M, with a high of $-150.38M and a low of $-155.90M. This is -311.30% lower than Exact Sciences's previous annual EBITDA (Sep 23) of $72.03M.

Exact Sciences Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111493471788771271489151077986
Net Income-------------$794.00K$-81.03M$-74.15M$-127.75M$-148.76M$-166.06M$-180.94M$-220.61M$-166.94M$-176.91M$-31.16M$-436.81M$-219.88M$-86.14M$-105.70M$77.94M$-40.46M
Avg Forecast$27.98M$36.82M$31.70M$-44.52M$-769.67K$8.70M$-4.32M$-56.27M$-60.96M$-36.20M$-62.89M$-225.07M$-78.16M$-87.12M$-87.74M$-204.61M$-186.67M$-197.94M$-191.87M$-186.01M$-154.82M$-155.97M$-137.91M$-51.19M$-35.69M$-98.74M$-119.10M$-84.20M$-65.28M$-75.00M
High Forecast$28.54M$37.56M$32.33M$-43.61M$-753.90K$8.88M$-4.23M$-20.84M$-47.63M$-35.46M$-61.61M$-180.06M$-72.26M$-59.90M$-85.94M$-163.69M$-149.34M$-197.94M$-191.87M$-148.81M$-154.82M$-155.97M$-137.91M$-40.95M$-35.69M$-98.74M$-119.10M$-67.36M$-65.28M$-75.00M
Low Forecast$27.41M$36.06M$31.05M$-45.41M$-785.12K$8.52M$-4.41M$-85.44M$-70.48M$-36.93M$-64.16M$-270.09M$-91.43M$-119.80M$-89.50M$-245.53M$-224.01M$-197.94M$-191.87M$-223.21M$-154.82M$-155.97M$-137.91M$-61.43M$-35.69M$-98.74M$-119.10M$-101.04M$-65.28M$-75.00M
Surprise %--------------0.01%0.92%0.36%0.68%0.75%0.87%0.97%1.42%1.07%1.28%0.61%12.24%2.23%0.72%1.26%-1.19%0.54%

Exact Sciences's average Quarter net income forecast for Dec 23 is $-78.16M, with a range of $-91.43M to $-72.26M. EXAS's average Quarter net income forecast represents a -9943.24% decrease compared to the company's last Quarter net income of $794.00K (Sep 23).

Exact Sciences SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111493471788771271489151077986
SG&A-------------$390.55M$414.45M$404.26M$404.11M$379.70M$397.60M$401.98M$463.71M$383.12M$362.43M$453.84M$312.21M$252.08M$225.60M$281.70M$264.10M$166.80M
Avg Forecast$698.94M$683.85M$669.61M$616.82M$627.26M$616.96M$596.00M$546.01M$543.33M$560.44M$539.50M$500.03M$499.48M$482.24M$470.01M$454.58M$392.37M$392.26M$390.15M$413.25M$351.15M$336.22M$329.15M$303.81M$347.12M$263.82M$178.60M$224.41M$232.55M$168.97M
High Forecast$709.73M$694.41M$679.94M$626.34M$636.94M$626.49M$605.20M$551.84M$545.90M$560.61M$539.50M$600.04M$511.63M$488.65M$477.26M$545.49M$470.85M$392.26M$390.15M$495.90M$351.15M$336.22M$329.15M$303.81M$347.12M$263.82M$178.60M$269.29M$232.55M$168.97M
Low Forecast$687.92M$673.07M$659.05M$607.10M$617.37M$607.24M$586.60M$535.89M$540.57M$560.27M$539.50M$400.03M$493.51M$476.68M$462.60M$363.66M$313.90M$392.26M$390.15M$330.60M$351.15M$336.22M$329.15M$303.81M$347.12M$263.82M$178.60M$179.52M$232.55M$168.97M
Surprise %-------------0.81%0.88%0.89%1.03%0.97%1.02%0.97%1.32%1.14%1.10%1.49%0.90%0.96%1.26%1.26%1.14%0.99%

Exact Sciences's average Quarter SG&A projection for Dec 23 is $499.48M, based on 7 Wall Street analysts, with a range of $493.51M to $511.63M. The forecast indicates a 27.89% rise compared to EXAS last annual SG&A of $390.55M (Sep 23).

Exact Sciences EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111493471788771271489151077986
EPS--------------$-0.45$-0.42$-0.72$-0.84$-0.94$-1.04$-1.28$-0.97$-1.03$-0.18$-2.79$-1.46$-0.58$-0.71$0.56$-0.31
Avg Forecast$0.15$0.20$0.17$-0.24$-0.00$0.05$-0.02$-0.30$-0.33$-0.20$-0.34$-0.47$-0.42$-0.47$-0.47$-0.73$-0.79$-1.07$-1.04$-1.10$-0.84$-0.85$-0.75$-0.96$-0.19$-0.54$-0.65$-0.58$-0.35$-0.41
High Forecast$0.15$0.20$0.17$-0.24$-0.00$0.05$-0.02$-0.11$-0.26$-0.19$-0.33$-0.47$-0.39$-0.32$-0.47$-0.71$-0.78$-1.07$-1.04$-1.10$-0.84$-0.85$-0.75$-0.96$-0.19$-0.54$-0.65$-0.58$-0.35$-0.41
Low Forecast$0.15$0.20$0.17$-0.25$-0.00$0.05$-0.02$-0.46$-0.38$-0.20$-0.35$-0.48$-0.49$-0.65$-0.48$-0.74$-0.81$-1.07$-1.04$-1.10$-0.84$-0.85$-0.75$-0.96$-0.19$-0.54$-0.65$-0.58$-0.35$-0.41
Surprise %--------------0.01%0.95%0.58%0.91%0.78%0.90%0.95%1.52%1.15%1.38%0.19%14.41%2.73%0.90%1.22%-1.58%0.76%

According to 7 Wall Street analysts, Exact Sciences's projected average Quarter EPS for Dec 23 is $-0.42, with a low estimate of $-0.49 and a high estimate of $-0.39. This represents a -9712.05% decrease compared to EXAS previous annual EPS of - (Sep 23).

Exact Sciences Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MYGNMyriad Genetics$13.82$30.20118.52%Hold
CDNACareDx$22.14$37.5069.38%Buy
CSTLCastle Biosciences$28.14$40.5043.92%Buy
EXASExact Sciences$60.37$77.4328.26%Buy
DHRDanaher$233.53$292.4025.21%Buy
TMOThermo Fisher Scientific$528.84$640.8821.19%Buy
GHGuardant Health$34.84$40.6016.53%Buy
CRLCharles River Laboratories$189.33$209.0010.39%Buy
AAgilent$136.46$147.408.02%Buy
ILMNIllumina$143.12$147.783.26%Buy
TWSTTwist Bioscience$48.40$46.00-4.96%Buy
NTRANatera$168.21$151.50-9.93%Buy

EXAS Forecast FAQ

Is Exact Sciences a good buy?

Yes, according to 17 Wall Street analysts, Exact Sciences (EXAS) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 15 'Buy' recommendations, accounting for 94.12% of EXAS's total ratings.

What is EXAS's price target?

Exact Sciences (EXAS) average price target is $77.43 with a range of $65 to $95, implying a 30.35% from its last price of $59.4. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Exact Sciences stock go up soon?

According to Wall Street analysts' prediction for EXAS stock, the company can go up by 30.35% (from the last price of $59.4 to the average price target of $77.43), up by 59.93% based on the highest stock price target, and up by 9.43% based on the lowest stock price target.

Can Exact Sciences stock reach $90?

EXAS's highest twelve months analyst stock price target of $95 supports the claim that Exact Sciences can reach $90 in the near future.

What are Exact Sciences's analysts' financial forecasts?

Exact Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.05B (high $3.1B, low $3B), average EBITDA is $-727M (high $-715M, low $-738M), average net income is $-52.652M (high $-16.946M, low $-82.108M), average SG&A $2.39B (high $2.42B, low $2.35B), and average EPS is $-0.285 (high $-0.0917, low $-0.444). EXAS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.41B (high $3.47B, low $3.36B), average EBITDA is $-813M (high $-801M, low $-826M), average net income is $51.98M (high $54.82M, low $49.11M), average SG&A $2.67B (high $2.71B, low $2.63B), and average EPS is $0.281 (high $0.297, low $0.266).

Did the EXAS's actual financial results beat the analysts' financial forecasts?

Based on Exact Sciences's last annual report (Dec 2022), the company's revenue was $2.08B, beating the average analysts forecast of $1.99B by 4.68%. Apple's EBITDA was $-480M, missing the average prediction of $-528M by -9.15%. The company's net income was $-624M, missing the average estimation of $-762M by -18.23%. Apple's SG&A was $1.58B, missing the average forecast of $1.59B by -0.30%. Lastly, the company's EPS was $-3.54, missing the average prediction of $-4.006 by -11.63%. In terms of the last quarterly report (Sep 2023), Exact Sciences's revenue was $628.34M, beating the average analysts' forecast of $616.79M by 1.87%. The company's EBITDA was $72.03M, missing the average prediction of $-147M by -149.02%. Exact Sciences's net income was $794K, missing the average estimation of $-87.123M by -100.91%. The company's SG&A was $390.55M, missing the average forecast of $482.24M by -19.01%. Lastly, the company's EPS was $0.0044, missing the average prediction of $-0.471 by -100.93%